Skip to Content

AlloVir Inc Ordinary Shares ALVR

Morningstar Rating
$0.74 −0.02 (2.01%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ALVR is trading at a 41% premium.
Price
$0.75
Fair Value
$2.42
Uncertainty
Extreme
1-Star Price
$62.18
5-Star Price
$9.55
Economic Moat
Ghgr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALVR is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.76
Day Range
$0.730.79
52-Week Range
$0.583.75
Bid/Ask
$0.74 / $0.76
Market Cap
$85.64 Mil
Volume/Avg
68,216 / 391,034

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
112

Comparables

Valuation

Metric
ALVR
CTIC
ITOS
Price/Earnings (Normalized)
Price/Book Value
0.711.04
Price/Sales
14.71
Price/Cash Flow
Price/Earnings
ALVR
CTIC
ITOS

Financial Strength

Metric
ALVR
CTIC
ITOS
Quick Ratio
18.381.2012.80
Current Ratio
18.481.2713.51
Interest Coverage
−3.20
Quick Ratio
ALVR
CTIC
ITOS

Profitability

Metric
ALVR
CTIC
ITOS
Return on Assets (Normalized)
−52.15%−46.52%−16.56%
Return on Equity (Normalized)
−65.46%−18.86%
Return on Invested Capital (Normalized)
−59.04%−143.40%−22.78%
Return on Assets
ALVR
CTIC
ITOS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
DkjmxysvRhby$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
NhpgjfgYdqtw$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
NslvqzqsVlfmcsm$117.2 Bil
Moderna Inc
MRNA
QpcvngljmSzw$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
DhbssjfrMlhnmlf$30.1 Bil
argenx SE ADR
ARGX
GytsmwwfKlwk$28.0 Bil
BioNTech SE ADR
BNTX
WjrtsjbXmn$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
HwvwwlkyxWlqphj$16.0 Bil
United Therapeutics Corp
UTHR
KyvyknspWdln$14.6 Bil
Incyte Corp
INCY
DvjkbdsdTtnhj$13.0 Bil

Sponsor Center